28.08.2014
Vita 34 AG DE000A0BL849
DGAP-News: Vita 34 AG: Successful Annual General Meeting 2014
DGAP-News: Vita 34 AG / Key word(s): AGM/EGM
Vita 34 AG: Successful Annual General Meeting 2014
28.08.2014 / 18:57
---------------------------------------------------------------------
Vita 34 AG: Successful Annual General Meeting 2014
Leipzig, 28 August 2014 - Vita 34 AG (WKN A0BL84), a pioneer in the storage
of stem cells from umbilical cord blood and tissue, and a specialist in
cryo-preservation, successfully conducted its Annual General Meeting 2014
today in Leipzig. 32.2 percent of capital stock took advantage of the
opportunity to exercise voting rights. Dr. André Gerth, Chairman of the
Management Board of this stem cell bank that is market leader in the
German-speaking countries gave the past fiscal year a positive review, and
he provided insight into the Vita 34 AG growth strategy.
All of the Supervisory Board members and the Management Board in office in
fiscal year 2013 were granted discharge within the context of the Annual
General Meeting. The Annual General Meeting authorized the Management Board
of Vita 34 to issue once or multiple times individually registered, no-par
value common stock in exchange for cash or consideration in kind. To this
end, authorized capital in the amount of EUR 1,513,250.00 was created (this
is equivalent to some 50 percent of the current nominal capital).
Dr. André Gerth outlined the positive development of Vita 34 AG in the past
fiscal year to the shareholders. The consistent implementation of the
growth strategy is intended to bolster profitability, in this year too, and
to secure the success of the company in the medium and long-term: "In 2013
we were successful in increasing profitability significantly, while keeping
revenues stable. We see growth opportunities in the coming years, in
particular through the expansion of our product range with 'VitaPlusCord'
[VitaPlusNabelschnur], the continuous expansion of our geographical
presence, and the intensification of research activities." In addition, Dr.
Gerth pointed out the future potential for Vita 34 AG to pay dividends: "By
eliminating the balance sheet loss in accordance with German commercial law
by accessing a capital reserve, we have for the first time created the
prerequisites for paying a dividend in the future. This will increase the
attractiveness of the Vita 34 shares on the capital markets."
The detailed voting results can be found at www.vita34group.de in the
"Annual General Meeting" section.
Company profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood and cord tissue. The basis
for its successful work is an outstanding position in the technological
segment of cryo-preservation. Here, cells and tissue are preserved alive at
some -190ºC for long periods of time, and can be used if needed in the
context of medical treatment. Parents of more than 106,000 children are
already taking advantage of this offering and have provided for their
children with a stem cell deposit at Vita 34. To date, 27 therapeutic
applications have been performed with stem cell preparations stored at Vita
34.
---------------------------------------------------------------------
28.08.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: [email protected]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
284544 28.08.2014
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Vita 34 AG ISIN: DE000A0BL849 können Sie bei EQS abrufen
Biotechnologie , A0BL84 , V3V , XETR:V3V